EV

Esperante Ventures

Europe, Noord-Holland, The Netherlands, Hoofddorp

Description

Esperante is a private limited Netherlands-based seed investments company incorporated in January 2004.

Investor Profile

Esperante Ventures has made 20 investments, with 1 in the past 12 months and 20% as lead.

Stage Focus

  • Series Unknown (50%)
  • Series B (15%)
  • Series A (15%)
  • Seed (15%)
  • Series C (5%)

Country Focus

  • United Kingdom (70%)
  • United States (10%)
  • Switzerland (10%)
  • Germany (5%)
  • Israel (5%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Health Diagnostics
  • Pharmaceutical
  • Medical Device
  • Clinical Trials
  • Life Science
  • Personal Health
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Esperante Ventures frequently co-invest with?

Longwall Venture
Europe, Oxfordshire, United Kingdom, Harwell
Co-Investments: 3
GV
Europe, Cambridgeshire, United Kingdom, Cambridge
Co-Investments: 1
Oxford Technology Management
Europe, Oxfordshire, United Kingdom, Oxford
Co-Investments: 1
NV
Europe, England, United Kingdom, London
Co-Investments: 2
IS
Europe, Norfolk, United Kingdom, Norwich
Co-Investments: 1
Catapult Ventures
Europe, Leicester, United Kingdom, Enderby
Co-Investments: 2
Future Planet Capital
Europe, England, United Kingdom, London
Co-Investments: 2
Northstar Ventures
Europe, Newcastle upon Tyne, United Kingdom, Newcastle Upon Tyne
Co-Investments: 4
Wellcome Trust
Europe, England, United Kingdom, London
Co-Investments: 2
Spark Ventures
Europe, England, United Kingdom, London
Co-Investments: 2

Which angels does Esperante Ventures often collaborate with?

JM
Europe, Isle of Man
Shared Deals: 1

What are some of recent deals done by Esperante Ventures?

Amlo Biosciences

Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom

AMLo Biosciences has identified two proteins (AMBLor™) in the skin overlying the primary tumour that are lost in high-risk melanoma.

Biotechnology
Series UnknownDec 3, 2024
Amount Raised: $2,027,873
Acousia Therapeutics

Tübingen, Baden-Wurttemberg, Germany

Acousia Therapeutics is a privately held biotech company.

BiotechnologyHealth CareTherapeutics
Series UnknownJan 9, 2024
Spiral Therapeutics

San Francisco, California, United States

Spiral Therapeutics is a clinical-stage pharmaceutical company delivering therapies for hearing loss.

BiotechnologyHealth CareMedicalPharmaceutical
Series UnknownAug 30, 2023
Pneumagen

Saint Andrews, Fife, United Kingdom

Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.

BiotechnologyHealth CareWellness
Series UnknownJun 1, 2023
Amount Raised: $10,021,032
Amlo Biosciences

Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom

AMLo Biosciences has identified two proteins (AMBLor™) in the skin overlying the primary tumour that are lost in high-risk melanoma.

Biotechnology
Series UnknownApr 21, 2022
Amount Raised: $3,191,031
Versantis

Zürich, Zurich, Switzerland

Versantis is a pharmaceutical company developing medicine to revolutionize the care of patients.

Health CareHealth DiagnosticsPharmaceuticalTherapeutics
Series BSep 18, 2019
Amount Raised: $16,046,406
Arquer Diagnostics

Sunderland, Cumbria, United Kingdom

Arquer Diagnostics is a diagnostics company focused on the development and commercialisation of a non-invasive immunoassay diagnostic test.

BiotechnologyHealth CareHealth DiagnosticsMedical Device
Series BOct 3, 2017
Amount Raised: $2,780,853
Oxford Cancer Biomarkers

Oxford, Oxfordshire, United Kingdom

Oxford Cancer is developing and commercialising a suite of colorectal cancer biomarker tests to improve the current treatment pathway.

BiopharmaBiotechnologyHealth Care
Series UnknownDec 14, 2015
Arquer Diagnostics

Sunderland, Cumbria, United Kingdom

Arquer Diagnostics is a diagnostics company focused on the development and commercialisation of a non-invasive immunoassay diagnostic test.

BiotechnologyHealth CareHealth DiagnosticsMedical Device
Series UnknownJan 16, 2015
Amount Raised: $3,030,960
Arquer Diagnostics

Sunderland, Cumbria, United Kingdom

Arquer Diagnostics is a diagnostics company focused on the development and commercialisation of a non-invasive immunoassay diagnostic test.

BiotechnologyHealth CareHealth DiagnosticsMedical Device
SeedFeb 14, 2014
Amount Raised: $719,194